<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drug\PMC7545798\results\search\drug\results.xml">
  <result pre="HIV on ART -Case report HIV Latent TB SARS-CoV N/A" exact="Abacavir" post="300â€‰mg Efavirenz 600â€‰mg Kaletra Tenofovir 300â€‰mg Ribavirin 1200â€‰mg prednisolone"/>
  <result pre="ART -Case report HIV Latent TB SARS-CoV N/A Abacavir 300â€‰mg" exact="Efavirenz" post="600â€‰mg Kaletra Tenofovir 300â€‰mg Ribavirin 1200â€‰mg prednisolone 25â€‰mg Diagnosed"/>
  <result pre="report HIV Latent TB SARS-CoV N/A Abacavir 300â€‰mg Efavirenz 600â€‰mg" exact="Kaletra" post="Tenofovir 300â€‰mg Ribavirin 1200â€‰mg prednisolone 25â€‰mg Diagnosed with PTB"/>
  <result pre="TB SARS-CoV N/A Abacavir 300â€‰mg Efavirenz 600â€‰mg Kaletra Tenofovir 300â€‰mg" exact="Ribavirin" post="1200â€‰mg prednisolone 25â€‰mg Diagnosed with PTB during hospitalization Mild"/>
  <result pre="N/A Abacavir 300â€‰mg Efavirenz 600â€‰mg Kaletra Tenofovir 300â€‰mg Ribavirin 1200â€‰mg" exact="prednisolone" post="25â€‰mg Diagnosed with PTB during hospitalization Mild course SARS"/>
  <result pre="old female with confirmed COVID-19 Case study PTB COVID-19 N/A" exact="hydroxychloroquine" post="400â€‰mg twice daily in addition to antibiotics. Anti TB"/>
  <result pre="76â€‰years -Case series Previous TB PTB COVID-19 N/A Lopinavir +" exact="Ritonavir" post="Arbidol Methyl prednisolone Antibiotics Traditional Chinese medicine Intravenous immunoglobulin"/>
  <result pre="Previous TB PTB COVID-19 N/A Lopinavir + Ritonavir Arbidol Methyl" exact="prednisolone" post="Antibiotics Traditional Chinese medicine Intravenous immunoglobulin Ventilatory support Antituberculosis"/>
  <result pre="and history of Parkinsonâ€™s disease. Case study PTB COVID-19 N/A" exact="Hydroxychloroquine" post="Oxygen supplementation Anti-TB drugs TB diagnosed in hospitalization Critical"/>
  <result pre="Case study Disseminated TB COVID-19 N/A COVID-19 convalescent plasma Favipiravir" exact="meropenem" post="Ventilatory support Anti-TB drugs TB diagnosed in hospitalization Critical"/>
  <result pre="diabetic, with confirmed COVID-19 Case study PTB COVID-19 N/A Lopinavir/ritonavir" exact="Ribavirin" post="Dexamethasone Prophylactic anticoagulation Supportive ICU care Anti-TB drugs Previous"/>
  <result pre="confirmed COVID-19/TB co-infection Case series PTB COVID-19 N/A Arbidol Moxifloxacin" exact="Linezolid" post="immunomodulatory therapy with thymopentin Ventilatory support Anti-TB drugs The"/>
  <result pre="HIV 20 confirmed COVID-19/TB cases Retrospective cohort study (Cohort B)" exact="Hydroxychloroquine" post="Lopinavir/ ritonavir Azythromycin Empiric antibiotic Enoxaparine 4000â€‰IU Dexamethasone Oxygen"/>
  <result pre="confirmed COVID-19/TB cases Retrospective cohort study (Cohort B) Hydroxychloroquine Lopinavir/" exact="ritonavir" post="Azythromycin Empiric antibiotic Enoxaparine 4000â€‰IU Dexamethasone Oxygen through non-rebreather,"/>
  <result pre="A case of SARS-CoV/HIV/TB co-infection [31] was managed with abacavir/efavirenz/kaletra/tenofovir/ribavirin," exact="prednisolone" post="and anti TB drugs and another case with SARS-CoV/TB"/>
  <result pre="the Xpert MTB / RIF assay detects M. tuberculosis and" exact="rifampicin" post="resistance within less than two hours [55]. Xpert MTB/RIF"/>
  <result pre="positive and the culture is negative, start TB preventive treatment." exact="Isoniazid" post="monotherapy for six (6) months is recommended for the"/>
  <result pre="in high burden HIV/TB countries [57]. Rifampicin or rifapentine plus" exact="isoniazid" post="daily for three (3) months should be offered as"/>
  <result pre="as an alternative to six (6) months of isoniazid. However," exact="rifampicin" post="and rifapentine should be prescribed with caution in HIV/COVID-19"/>
  <result pre="a wide variety of pathogens [58], including SARS-CoV. Lopinavir /" exact="ritonavir" post="(LPV/r) has a moderate anti-SARS-CoV-2 antiviral activity which works"/>
  <result pre="studies were low of power. Drug-drug interactions between PIs and" exact="rifampicin" post="are known in HIV/TB co-infection. Studies have demonstrated that"/>
  <result pre="HIV/TB co-infection. Studies have demonstrated that co-administration of PIs with" exact="rifampicin" post="reduces PIs systemic concentration to less than 75% (cytochrome"/>
  <result pre="may compromise COVID-19 treatment. Remdesivir should also not associate to" exact="rifampicin" post="in COVID-19/TB co-infection because of strong induction [64]. A"/>
  <result pre="of strong induction [64]. A recent review has reported that" exact="chloroquine" post="phosphate and hydroxychloroquine showed favorable outcomes in the recovery"/>
  <result pre="[64]. A recent review has reported that chloroquine phosphate and" exact="hydroxychloroquine" post="showed favorable outcomes in the recovery of COVID-19 patients"/>
  <result pre="outcomes in the recovery of COVID-19 patients [26, 65â€&quot;68]. Both" exact="chloroquine" post="and hydroxychloroquine are metabolized by hepatic cytochrome P450 enzyme"/>
  <result pre="the recovery of COVID-19 patients [26, 65â€&quot;68]. Both chloroquine and" exact="hydroxychloroquine" post="are metabolized by hepatic cytochrome P450 enzyme 2D6 (CYP2D6)"/>
  <result pre="CYP3A4 and CYP2D6 [70]. The reduction in the efficacy of" exact="chloroquine" post="when administered in conjunction with rifampicin may be due"/>
  <result pre="in the efficacy of chloroquine when administered in conjunction with" exact="rifampicin" post="may be due to the inducing effect of rifampicin"/>
  <result pre="with rifampicin may be due to the inducing effect of" exact="rifampicin" post="on multidrug resistance associated protein (MRP) and development of"/>
  <result pre="associated protein (MRP) and development of CYP450 [70]. Additionally, high-dose" exact="chloroquine" post="is more toxic than lower dose [64]. This is"/>
  <result pre="than lower dose [64]. This is why; studies should clarify" exact="chloroquine" post="and hydroxychloroquine dose adjustment in COVID-19/TB co-infection. Based on"/>
  <result pre="dose [64]. This is why; studies should clarify chloroquine and" exact="hydroxychloroquine" post="dose adjustment in COVID-19/TB co-infection. Based on the above,"/>
  <result pre="adjustments should be taken into consideration in case PIs, chloroquine," exact="hydroxychloroquine" post="and remdesivir are administered with rifampicin. Another option is"/>
  <result pre="remdesivir are administered with rifampicin. Another option is to shift" exact="rifampicin" post="to rifabutin or adapted TB regimens without rifampicin. In"/>
  <result pre="administered with rifampicin. Another option is to shift rifampicin to" exact="rifabutin" post="or adapted TB regimens without rifampicin. In contrast, clofazimine"/>
  <result pre="to rifabutin or adapted TB regimens without rifampicin. In contrast," exact="clofazimine" post="used in MDR-TB is a strong inhibitor of PIs,"/>
  <result pre="national guidelines and continue ART. Preferred COVID-19 antivirals are oseltamivir," exact="chloroquine" post="or hydroxychloroquine associated to LV/r or darunavir/cobicistat and Azithromycin"/>
  <result pre="and continue ART. Preferred COVID-19 antivirals are oseltamivir, chloroquine or" exact="hydroxychloroquine" post="associated to LV/r or darunavir/cobicistat and Azithromycin may be"/>
  <result pre="oseltamivir, chloroquine or hydroxychloroquine associated to LV/r or darunavir/cobicistat and" exact="Azithromycin" post="may be indicated [68]. Chloroquine: 1â€‰g PO once on"/>
  <result pre="1, then 400â€‰mg PO once daily for 4â€&quot;7â€‰days [64] or" exact="lopinavir" post="400â€‰mg/ritonavir 100â€‰mg PO twice [65]. All of them should"/>
  <result pre="PO twice [65]. All of them should be associated with" exact="Azithromycin" post="[64]. Drugs interactions should be reviewed as described above."/>
  <result pre="recommended in severe/critical COVID-19 however this cannot be administered with" exact="rifampicin" post="[64]. Short period low-dose corticosteroid therapy is preferred over"/>
  <result pre="severe COVID-19. Short period low-dose corticosteroid therapy, anticoagulant therapy and" exact="norepinephrine" post="as the first-choice vasopressor are recommended [64]. Anticoagulant therapy"/>
  <result pre="in meta-analyses http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp. Accessed 29 July 2020. 26.WangMCaoRZhangLYangXLiuJXuMet al.Remdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in"/>
  <result pre="J Epidemiol202041E057 46.Zhang H, Yuan Y. Efficacy and Safety of" exact="Nintedanib" post="in the Treatment of Pulmonary Fibrosis in Patients with"/>
  <result pre="amplification test for rapid and simultaneous detection of TB and" exact="rifampicin" post="resistance2016 56.Cattamanchi A, Ssewenyana I, Nabatanzi R, Miller CR,"/>
  <result pre="Int AIDS Soc. 2020. 10.1002/:jia2.25489. 62.AcostaEPKendallMAGerberJGAlston-SmithBKoletarSLZolopaARet al.Effect of concomitantly administered" exact="rifampin" post="on the pharmacokinetics and safety of atazanavir administered twice"/>
  <result pre="of concomitantly administered rifampin on the pharmacokinetics and safety of" exact="atazanavir" post="administered twice dailyAntimicrob Agents Chemother20075193104311010.1128/AAC.00341-0717576825 63.KaranjaJKKiboiNGNebereSNHO A.Highly active antiretroviral"/>
  <result pre="vitro antiviral activity and projection of optimized dosing design of" exact="hydroxychloroquine" post="for the treatment of severe acute respiratory syndrome coronavirus"/>
  <result pre="review. Inf Prev Pract 2020; https://doi.org/10.1016/j.infpip.2020.100061. 69.JuurlinkDNSafety considerations with chloroquine," exact="hydroxychloroquine" post="and azithromycin in the management of SARS-CoV-2 infectionCan Med"/>
  <result pre="Prev Pract 2020; https://doi.org/10.1016/j.infpip.2020.100061. 69.JuurlinkDNSafety considerations with chloroquine, hydroxychloroquine and" exact="azithromycin" post="in the management of SARS-CoV-2 infectionCan Med Assoc J202019217E450E45310.1503/cmaj.20052832269021"/>
  <result pre="Assoc J202019217E450E45310.1503/cmaj.20052832269021 70.SousaMPozniakABoffitoMPharmacokinetics and pharmacodynamics of drug interactions involving rifampicin," exact="rifabutin" post="and antimalarial drugsJ Antimicrob Chemother200862587287810.1093/jac/dkn33018713760 71.MarquezBVan BambekeFABC multidrug transporters:"/>
 </snippets>
</snippetsTree>
